Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

27.3%

3 terminated/withdrawn out of 11 trials

Success Rate

70.0%

-16.6% vs industry average

Late-Stage Pipeline

27%

3 trials in Phase 3/4

Results Transparency

29%

2 of 7 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2

2(28.6%)

Phase 1

2(28.6%)

Phase 3

2(28.6%)

Phase 4

1(14.3%)

7Total

Phase 2(2)

Phase 1(2)

Phase 3(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (11)

Showing 11 of 11 trials

NCT05388474Completed

A Prospective and Retrospective Observational Study of Multidrug-Resistant Patient Outcomes With and Without Ibalizumab

Role: lead

NCT04706962Phase 1Active Not Recruiting

TH1902 in Patients With Advanced Solid Tumors

Role: lead

NCT05383456Completed

The Visceral Adiposity Measurement and Observation Study

Role: lead

NCT05495204Completed

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

Role: collaborator

NCT00608023Phase 3Completed

TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy

Role: lead

NCT01388920Phase 2Terminated

Efficacy and Safety Study of Tesamorelin in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Muscle Wasting

Role: lead

NCT01591902Phase 4Terminated

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

Role: lead

NCT01579695Terminated

Long-term Observational Study in HIV Subjects Exposed to EGRIFTA®

Role: lead

NCT02012556Phase 1Completed

Pharmacokinetic and Pharmacodynamic Study of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Positive Patients

Role: lead

NCT00123253Phase 3Completed

TH9507 in Patients With HIV-Associated Lipodystrophy

Role: lead

NCT01264497Phase 2Completed

Safety Study of TH9507 in Subjects With Stable, Type 2 Diabetes

Role: lead

All 11 trials loaded